Pfizer Geodon IM Should Not Be Given To Patients Taking Oral Form - Cmte.
Executive Summary
Pfizer's intramuscular ziprasidone (Geodon) should be restricted to patients not taking the oral formulation of the drug, FDA's Psychopharmacological Drugs Advisory Committee suggested at its Feb. 15 review of the IM formulation.
You may also be interested in...
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Lilly Zyprexa IM Agitation Use Should Be Limited To Patients Studied In Trials
Lilly's antipsychotic Zyprexa intramuscular injection is safe and effective for the treatment of agitation in schizophrenia, bipolar I disorder and dementia, FDA's Psychopharmacological Drugs Advisory Committee concluded in a unanimous vote Feb. 14.